Literature DB >> 11676857

Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.

S Mikami1, K Ohashi, Y Usui, T Nemoto, K Katsube, M Yanagishita, M Nakajima, K Nakamura, M Koike.   

Abstract

Heparan sulfate proteoglycans play important biological roles in cell-cell and cell-matrix adhesion, and are closely associated with growth factor actions. Loss of syndecan-1, a cell surface-bound heparan sulfate proteoglycan, has been reported for advanced head and neck carcinomas, and expression of endoglycosidic heparanase, which cleaves heparan sulfate glycosaminoglycans (HS-GAGs), is associated with invasion and metastatic potential of malignant tumors. Paraffin sections of 103 primary esophageal squamous cell carcinomas were immunohistochemically examined for the expression of syndecan-1 core protein, HS-GAGs and heparanase protein, and the results were compared with various clinicopathological parameters, such as invasion depth. For 16 cases, fresh tumor samples were quantitatively analyzed for heparanase and syndecan-1 mRNA expression by real-time RT-PCR in addition to the immunohistochemical studies. Syndecan-1 core protein and HS-GAGs expression was significantly decreased in pT2 and pT3 cases compared with their pTis and pT1 counterparts. Decreased expression of core protein and HS-GAGs was correlated with the incidence of lymphatic invasion, and venous involvement. Furthermore, decreased expression of HS-GAGs was correlated positively with the incidence of nodal metastasis and distant organ metastasis, and negatively with the grade of tumor cell differentiation. The percentage of cytoplasmic heparanase protein-positive cases increased significantly in pT2 and pT3 cases compared to that in pTis and pT1 cases, and this was associated with lymphatic invasion, and venous and lymph nodal involvement. The level of heparanase mRNA was inversely correlated with the degree of HS-GAGs expression rather than core protein. In conclusion, loss of syndecan-1 and heparanase overexpression in esophageal squamous cell carcinomas are closely associated with malignant potential. Regarding the mechanism of loss of HS-GAGs, heparanase upregulation appears to play an important role.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676857      PMCID: PMC5926620          DOI: 10.1111/j.1349-7006.2001.tb01061.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  43 in total

Review 1.  Integrins.

Authors:  E Ruoslahti
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

2.  Syndecan-1: a new prognostic marker in laryngeal cancer.

Authors:  J O Pulkkinen; M Penttinen; M Jalkanen; P Klemi; R Grénman
Journal:  Acta Otolaryngol       Date:  1997-03       Impact factor: 1.494

3.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.

Authors:  M D Hulett; C Freeman; B J Hamdorf; R T Baker; M J Harris; C R Parish
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

4.  Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study.

Authors:  K Hayashi; M Hayashi; M Jalkanen; J H Firestone; R L Trelstad; M Bernfield
Journal:  J Histochem Cytochem       Date:  1987-10       Impact factor: 2.479

5.  Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma.

Authors:  I B Bayer-Garner; R D Sanderson; B R Smoller
Journal:  J Cutan Pathol       Date:  1999-09       Impact factor: 1.587

6.  Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.

Authors:  M Rintala; P Inki; P Klemi; M Jalkanen; S Grénman
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

7.  Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells.

Authors:  M J Stanley; B F Liebersbach; W Liu; D J Anhalt; R D Sanderson
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

8.  Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation.

Authors:  P Inki; F Stenbäck; L Talve; M Jalkanen
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

9.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

Authors:  P M Holland; R D Abramson; R Watson; D H Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.

Authors:  K J Livak; S J Flood; J Marmaro; W Giusti; K Deetz
Journal:  PCR Methods Appl       Date:  1995-06
View more
  30 in total

1.  The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma.

Authors:  Hyunjin Kim; Dong Soon Choi; Suk-Joon Chang; Jae Ho Han; Churl K Min; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

Review 2.  Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities.

Authors:  Solomon A Agere; Eugene Y Kim; Nahid Akhtar; Salahuddin Ahmed
Journal:  J Cell Physiol       Date:  2018-03-25       Impact factor: 6.384

3.  Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.

Authors:  Gábor Sobel; István Szabó; Csilla Páska; András Kiss; Ilona Kovalszky; Anna Kádár; Ferenc Paulin; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

4.  Unraveling the specificity of heparanase utilizing synthetic substrates.

Authors:  Sherket B Peterson; Jian Liu
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

5.  Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.

Authors:  Ben Davidson; Lina Vintman; Eyal Zcharia; Carlos Bedrossian; Aasmund Berner; Søren Nielsen; Neta Ilan; Israel Vlodavsky; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway.

Authors:  Haiguo Sun; Yunping Hu; Zhennan Gu; Rick T Owens; Yong Q Chen; Iris J Edwards
Journal:  Carcinogenesis       Date:  2011-07-18       Impact factor: 4.944

7.  Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells.

Authors:  Edward McKenzie; Kathryn Young; Margaret Hircock; James Bennett; Maina Bhaman; Robert Felix; Paul Turner; Alasdair Stamps; David McMillan; Giles Saville; Stanley Ng; Sean Mason; Daniel Snell; Darren Schofield; Haiping Gong; Reid Townsend; John Gallagher; Martin Page; Raj Parekh; Colin Stubberfield
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

8.  Heparanase mRNA expression and point mutation in hepatocellular carcinoma.

Authors:  Xiao-Peng Chen; Yin-Bib Liu; Jing Rui; Shu-You Peng; Cheng-Hong Peng; Zi-Yan Zhou; Liang-Hui Shi; Hong-Wei Shen; Bin Xu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells.

Authors:  Haiguo Sun; Isabelle M Berquin; Rick T Owens; Joseph T O'Flaherty; Iris J Edwards
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Authors:  Laura Q M Chow; Daniel L Gustafson; Cindy L O'Bryant; Lia Gore; Michele Basche; Scott N Holden; Mark C Morrow; Stacy Grolnic; Brian R Creese; Kaye L Roberts; Kat Davis; Russell Addison; S Gail Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-05       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.